PDE2/PDE10-IN-1

Cat. No.: HY-U00427 Purity: 99.88%: FAQs
Data Sheet SDS COA Handling Instructions

Molarity Calculator

PDE2/PDE10-IN-1 is a phosphodiesterase 2 (PDE2) and PDE10 inhibitor with IC₅₀s of 29 and 480 nM, respectively.

For research use only. We do not sell to patients.

PDE2/PDE10-IN-1 Chemical Structure

CAS No. : 1426833-08-0

Size	Price	Stock	Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	USD 462	In-stock	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	USD 462	In-stock	Estimated Time of Arrival: December 31
Solid
5 mg	USD 420	In-stock	Estimated Time of Arrival: December 31
10 mg	USD 720	In-stock	Estimated Time of Arrival: December 31
25 mg	USD 1450	In-stock	Estimated Time of Arrival: December 31
50 mg	USD 2300	In-stock	Estimated Time of Arrival: December 31
100 mg	USD 3650	In-stock	Estimated Time of Arrival: December 31
200 mg		Get quote
500 mg		Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All Phosphodiesterase (PDE) Isoform Specific Products:

View All Isoforms

PDE1 PDE2 PDE3 PDE4 PDE5 PDE6 PDE7 PDE9 PDE10 PDE11 PDE12 PDE8 Autotaxin

Biological Activity
Protocol
Purity & Documentation
References
Customer Review

Description

PDE2/PDE10-IN-1 is a phosphodiesterase 2 (PDE2) and PDE10 inhibitor with IC₅₀s of 29 and 480 nM, respectively.

IC₅₀ & Target^[1]

hPDE2A

29 nM (IC₅₀)

rPDE10A

480 nM (IC₅₀)

hPDE4D

5890 nM (IC₅₀)

hPDE11A

6920 nM (IC₅₀)

Cellular Effect

Cell Line	Type	Value	Description	References
HEK293	IC₅₀	6920 nM Compound: 6	Inhibition of full length human PDE11A4 expressed in HEK cells by scintillation proximity assay Inhibition of full length human PDE11A4 expressed in HEK cells by scintillation proximity assay	[PMID: 25815146]
Sf9	IC₅₀	> 10000 nM Compound: 6	Inhibition of 6-His-tagged human recombinant PDE5A3 expressed in Sf9 cells by scintillation proximity assay Inhibition of 6-His-tagged human recombinant PDE5A3 expressed in Sf9 cells by scintillation proximity assay	[PMID: 25815146]
Sf9	IC₅₀	> 10000 nM Compound: 6	Inhibition of 6-His-tagged human recombinant PDE7A1 expressed in Sf9 cells by scintillation proximity assay Inhibition of 6-His-tagged human recombinant PDE7A1 expressed in Sf9 cells by scintillation proximity assay	[PMID: 25815146]
Sf9	IC₅₀	> 10000 nM Compound: 6	Inhibition of 6-His-tagged human recombinant PDE9A1 expressed in Sf9 cells by scintillation proximity assay Inhibition of 6-His-tagged human recombinant PDE9A1 expressed in Sf9 cells by scintillation proximity assay	[PMID: 25815146]
Sf9	IC₅₀	29 nM Compound: 6	Inhibition of 6-His-tagged human recombinant PDE2A expressed in Sf9 cells using [3H]cGMP incubated for 40 mins by scintillation proximity assay Inhibition of 6-His-tagged human recombinant PDE2A expressed in Sf9 cells using [3H]cGMP incubated for 40 mins by scintillation proximity assay	[PMID: 25815146]
Sf9	IC₅₀	480 nM Compound: 6	Inhibition of 6-His-tagged rat recombinant PDE10A expressed in Sf9 cells using [3H]cAMP incubated for 60 mins by scintillation proximity assay Inhibition of 6-His-tagged rat recombinant PDE10A expressed in Sf9 cells using [3H]cAMP incubated for 60 mins by scintillation proximity assay	[PMID: 25815146]
Sf9	IC₅₀	5890 nM Compound: 6	Inhibition of 6-His-tagged human recombinant PDE4D3 expressed in Sf9 cells by scintillation proximity assay Inhibition of 6-His-tagged human recombinant PDE4D3 expressed in Sf9 cells by scintillation proximity assay	[PMID: 25815146]

In Vitro

PDE2/PDE10-IN-1 (Compound 6) inhibits PDE2 and PDE10, respectively, with an IC₅₀ value of 29 and 480 nM. PDE2/PDE10-IN-1 also inhibits PDE11A and PDE4D with IC₅₀s of 6920 nM and 5890 nM, respectively. In addition PDE2/PDE10-IN-1 does not show significant inhibition of a panel of CYP450 enzymes (CYP1A2, 2C9, 2D6, 2C19, and 3A4). PDE2/PDE10-IN-1 is also inactive up to a concentration of 125 μg/mL in a bacterial mutagenicity assay^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

The PK properties of PDE2/PDE10-IN-1 are studied in rats after 2.5 mg/kg i.v. and 10 mg/kg p.o. administration. After i.v. administration, a rapid clearance is observed (t_1/2=0.47 h), which is not expected based on the in vitro metabolic stability in rat liver microsomes (rLMs). Interestingly, PDE2/PDE10-IN-1 shows much slower clearance after p.o. administration (t_1/2=2.36 h), resulting in good bioavailability and a maximum plasma concentration (C_max) of 997 ng/mL. PDE2/PDE10-IN-1 is assessed for its potential to cross the blood–brain barrier in rats after 10 mg/kg s.c. administration. PDE2/PDE10-IN-1 shows good formulatability with 10 to 20% HPβCD at pH>3.5. The brain concentration for PDE2/PDE10-IN-1 after 1 h administration is in the range of 370-895 ng/g with high brain free fractions and brain/plasma ratios. More specifically, PDE2/PDE10-IN-1, which is orally bioavailable, occupies PDE2 with an ED₅₀ of 21 mg/kg^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Molecular Weight

295.73

Formula

C₁₅H₁₀ClN₅

CAS No.

1426833-08-0

Appearance

Solid

Color

Off-white to brown

SMILES

CC1=NC2=C(C=NC=C2)N3C1=NN=C3C4=CC=CC=C4Cl

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Solvent & Solubility

In Vitro:

DMSO : 12.5 mg/mL (42.27 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	3.3815 mL	16.9073 mL	33.8146 mL
5 mM	0.6763 mL	3.3815 mL	6.7629 mL
10 mM	0.3381 mL	1.6907 mL	3.3815 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 1.25 mg/mL (4.23 mM); Clear solution

This protocol yields a clear solution of ≥ 1.25 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (12.5 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 1.25 mg/mL (4.23 mM); Clear solution

This protocol yields a clear solution of ≥ 1.25 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (12.5 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 1.25 mg/mL (4.23 mM); Clear solution

This protocol yields a clear solution of ≥ 1.25 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (12.5 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Purity & Documentation

Purity: 99.88%

Select Batch:

Data Sheet (316 KB) SDS (251 KB)

COA (260 KB) HNMR (101 KB) LCMS (246 KB)

Handling Instructions (2659 KB)

References

[1]. Rombouts FJ, et al. Pyrido[4,3-e][1,2,4]triazolo[4,3-a]pyrazines as Selective, Brain Penetrant Phosphodiesterase 2 (PDE2) Inhibitors. ACS Med Chem Lett. 2015 Jan 15;6(3):282-6. [Content Brief]

Animal Administration ^[1]	Rats^[1] Male Sprague-Dawley rats are fed with PDE2/PDE10-IN-1 (i.v., 2.5 mg/kg; p.o., 10 mg/kg). After administration, the clearance is observed. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
References	[1]. Rombouts FJ, et al. Pyrido[4,3-e][1,2,4]triazolo[4,3-a]pyrazines as Selective, Brain Penetrant Phosphodiesterase 2 (PDE2) Inhibitors. ACS Med Chem Lett. 2015 Jan 15;6(3):282-6. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	3.3815 mL	16.9073 mL	33.8146 mL	84.5366 mL
	5 mM	0.6763 mL	3.3815 mL	6.7629 mL	16.9073 mL
	10 mM	0.3381 mL	1.6907 mL	3.3815 mL	8.4537 mL
	15 mM	0.2254 mL	1.1272 mL	2.2543 mL	5.6358 mL
	20 mM	0.1691 mL	0.8454 mL	1.6907 mL	4.2268 mL
	25 mM	0.1353 mL	0.6763 mL	1.3526 mL	3.3815 mL
	30 mM	0.1127 mL	0.5636 mL	1.1272 mL	2.8179 mL
	40 mM	0.0845 mL	0.4227 mL	0.8454 mL	2.1134 mL

PDE2/PDE10-IN-1 Related Classifications

Neurological Disease

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

PDE2/PDE10-IN-11426833-08-0Phosphodiesterase (PDE)Inhibitorinhibitorinhibit

Your Recently Viewed Products:

Product Name

Salutation

Applicant Name *

Email Address *

Phone Number *

Organization Name *

Department *

Requested quantity *

Country or Region *

Remarks